[{"edinetCode":"E02474","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1344.0,"averageTemporaryStaff":88.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":80406500.0,"sharesOwendPercent":0.6677,"outstandingShares":null,"numberOfSubsidiary":11.0,"bps":497.32,"equityRatio":0.892,"cashAndCashEquivalents":22200000000.0,"assets":67143000000.0,"currentAssets":43964000000.0,"fixedAsset":23178000000.0,"tangibleFixedAssets":19577000000.0,"intangibleFixedAssets":2301000000.0,"investmentAndOtherAssets":1299000000.0,"liabilities":7157000000.0,"currentLiabilities":6025000000.0,"shorTermDept":47000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1131000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":82000000.0,"netAsset":59985000000.0,"capitalStock":58291000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":10432000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":1593000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":29375000000.0,"costOfSales":12422000000.0,"grossProfit":16952000000.0,"sgaExpenses":13749000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4101000000.0,"operatingIncome":3202000000.0,"nonOperatingIncome":445000000.0,"nonOperatingExpenses":68000000.0,"interestExpense":2000000.0,"ordinaryProfit":3579000000.0,"extraordinaryGain":2000000.0,"extraordinaryLoss":775000000.0,"incomeBeforeTax":2805000000.0,"incomeTaxes":1449000000.0,"netIncome":1356000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1352000000.0,"comprehensiveIncome":92000000.0,"eps":11.24,"dilutedEps":null,"dividendPerShare":null,"per":135.99,"roe":0.0226,"cashFlowFromOperatingActivities":3584000000.0,"depreciationAndCashflowFromOperatingActivities":1722000000.0,"cashFlowFromInvestingActivities":13493000000.0,"cashFlowFromFinancialActivities":-280000000.0,"changesInCashAndCashEquivalents":16631000000.0,"列1":"asr","submitDate":"2017\/6\/29","stockCode":4974,"accountingYear":"第15期（自　平成28年４月１日　至　平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1448.0,"averageTemporaryStaff":98.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":85181300.0,"sharesOwendPercent":0.7074,"outstandingShares":null,"numberOfSubsidiary":11.0,"bps":513.66,"equityRatio":0.898,"cashAndCashEquivalents":10051000000.0,"assets":68854000000.0,"currentAssets":35032000000.0,"fixedAsset":33821000000.0,"tangibleFixedAssets":18534000000.0,"intangibleFixedAssets":14163000000.0,"investmentAndOtherAssets":1123000000.0,"liabilities":6894000000.0,"currentLiabilities":5745000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1149000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":61959000000.0,"capitalStock":60144000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":12285000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":1707000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":32312000000.0,"costOfSales":13657000000.0,"grossProfit":18655000000.0,"sgaExpenses":15099000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4653000000.0,"operatingIncome":3555000000.0,"nonOperatingIncome":402000000.0,"nonOperatingExpenses":96000000.0,"interestExpense":19000000.0,"ordinaryProfit":3861000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":501000000.0,"incomeBeforeTax":3361000000.0,"incomeTaxes":1023000000.0,"netIncome":2338000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2335000000.0,"comprehensiveIncome":2455000000.0,"eps":19.39,"dilutedEps":null,"dividendPerShare":null,"per":104.79,"roe":0.0384,"cashFlowFromOperatingActivities":3935000000.0,"depreciationAndCashflowFromOperatingActivities":2568000000.0,"cashFlowFromInvestingActivities":-14755000000.0,"cashFlowFromFinancialActivities":-1205000000.0,"changesInCashAndCashEquivalents":-12149000000.0,"列1":"asr","submitDate":"2018\/6\/28","stockCode":4974,"accountingYear":"第16期（自　平成29年４月１日　至　平成30年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1435.0,"averageTemporaryStaff":18.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":85838200.0,"sharesOwendPercent":0.7128,"outstandingShares":null,"numberOfSubsidiary":8.0,"bps":531.57,"equityRatio":0.901,"cashAndCashEquivalents":9464000000.0,"assets":71040000000.0,"currentAssets":35275000000.0,"fixedAsset":35765000000.0,"tangibleFixedAssets":21404000000.0,"intangibleFixedAssets":12628000000.0,"investmentAndOtherAssets":1732000000.0,"liabilities":6945000000.0,"currentLiabilities":6017000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":927000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":64095000000.0,"capitalStock":63260000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":15401000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":749000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":35841000000.0,"costOfSales":15155000000.0,"grossProfit":20685000000.0,"sgaExpenses":15221000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4337000000.0,"operatingIncome":5463000000.0,"nonOperatingIncome":307000000.0,"nonOperatingExpenses":105000000.0,"interestExpense":null,"ordinaryProfit":5665000000.0,"extraordinaryGain":146000000.0,"extraordinaryLoss":988000000.0,"incomeBeforeTax":4823000000.0,"incomeTaxes":1149000000.0,"netIncome":3673000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3657000000.0,"comprehensiveIncome":2705000000.0,"eps":30.38,"dilutedEps":null,"dividendPerShare":null,"per":84.51,"roe":0.0581,"cashFlowFromOperatingActivities":5783000000.0,"depreciationAndCashflowFromOperatingActivities":2691000000.0,"cashFlowFromInvestingActivities":-5576000000.0,"cashFlowFromFinancialActivities":-541000000.0,"changesInCashAndCashEquivalents":-587000000.0,"列1":"asr","submitDate":"2019\/6\/27","stockCode":4974,"accountingYear":"第17期（自　2018年４月１日　至　2019年３月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.911,"cashAndCashEquivalents":12558000000.0,"assets":71402000000.0,"currentAssets":36050000000.0,"fixedAsset":35352000000.0,"tangibleFixedAssets":21812000000.0,"intangibleFixedAssets":12396000000.0,"investmentAndOtherAssets":1143000000.0,"liabilities":6248000000.0,"currentLiabilities":5207000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1041000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":65154000000.0,"capitalStock":64131000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":16272000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":930000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":8650000000.0,"costOfSales":2734000000.0,"grossProfit":5916000000.0,"sgaExpenses":3664000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":939000000.0,"operatingIncome":2251000000.0,"nonOperatingIncome":62000000.0,"nonOperatingExpenses":113000000.0,"interestExpense":null,"ordinaryProfit":2200000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":9000000.0,"incomeBeforeTax":2191000000.0,"incomeTaxes":595000000.0,"netIncome":1596000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1591000000.0,"comprehensiveIncome":1778000000.0,"eps":13.22,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":3874000000.0,"depreciationAndCashflowFromOperatingActivities":677000000.0,"cashFlowFromInvestingActivities":11000000.0,"cashFlowFromFinancialActivities":-821000000.0,"changesInCashAndCashEquivalents":3094000000.0,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4974,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":85693300.0,"sharesOwendPercent":0.7116,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.91,"cashAndCashEquivalents":10676000000.0,"assets":70837000000.0,"currentAssets":34108000000.0,"fixedAsset":36728000000.0,"tangibleFixedAssets":24011000000.0,"intangibleFixedAssets":11744000000.0,"investmentAndOtherAssets":972000000.0,"liabilities":6278000000.0,"currentLiabilities":4810000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1468000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":64558000000.0,"capitalStock":64615000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":16756000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":-146000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":16450000000.0,"costOfSales":6121000000.0,"grossProfit":10329000000.0,"sgaExpenses":7293000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1858000000.0,"operatingIncome":3035000000.0,"nonOperatingIncome":130000000.0,"nonOperatingExpenses":203000000.0,"interestExpense":null,"ordinaryProfit":2961000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":12000000.0,"incomeBeforeTax":2950000000.0,"incomeTaxes":870000000.0,"netIncome":2080000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2075000000.0,"comprehensiveIncome":1182000000.0,"eps":17.23,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":4709000000.0,"depreciationAndCashflowFromOperatingActivities":1352000000.0,"cashFlowFromInvestingActivities":-2283000000.0,"cashFlowFromFinancialActivities":-884000000.0,"changesInCashAndCashEquivalents":1212000000.0,"列1":"q2r","submitDate":"2019\/11\/13","stockCode":4974,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.902,"cashAndCashEquivalents":10241000000.0,"assets":71835000000.0,"currentAssets":35137000000.0,"fixedAsset":36697000000.0,"tangibleFixedAssets":24263000000.0,"intangibleFixedAssets":11498000000.0,"investmentAndOtherAssets":934000000.0,"liabilities":6947000000.0,"currentLiabilities":5504000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1442000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":64888000000.0,"capitalStock":65249000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":17390000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":-452000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":24558000000.0,"costOfSales":9767000000.0,"grossProfit":14791000000.0,"sgaExpenses":10911000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":2812000000.0,"operatingIncome":3879000000.0,"nonOperatingIncome":212000000.0,"nonOperatingExpenses":195000000.0,"interestExpense":2000000.0,"ordinaryProfit":3896000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":13000000.0,"incomeBeforeTax":3883000000.0,"incomeTaxes":1165000000.0,"netIncome":2717000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2708000000.0,"comprehensiveIncome":1512000000.0,"eps":22.49,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":4688000000.0,"depreciationAndCashflowFromOperatingActivities":2102000000.0,"cashFlowFromInvestingActivities":-2581000000.0,"cashFlowFromFinancialActivities":-929000000.0,"changesInCashAndCashEquivalents":777000000.0,"列1":"q3r","submitDate":"2020\/2\/14","stockCode":4974,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1485.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":84786200.0,"sharesOwendPercent":0.7041,"outstandingShares":null,"numberOfSubsidiary":8.0,"bps":552.23,"equityRatio":0.887,"cashAndCashEquivalents":14462000000.0,"assets":75009000000.0,"currentAssets":38387000000.0,"fixedAsset":36622000000.0,"tangibleFixedAssets":24213000000.0,"intangibleFixedAssets":11355000000.0,"investmentAndOtherAssets":1053000000.0,"liabilities":8418000000.0,"currentLiabilities":6248000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":2169000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":66591000000.0,"capitalStock":66360000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":18501000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":135000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":34565000000.0,"costOfSales":13459000000.0,"grossProfit":21105000000.0,"sgaExpenses":14830000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":3869000000.0,"operatingIncome":6274000000.0,"nonOperatingIncome":316000000.0,"nonOperatingExpenses":243000000.0,"interestExpense":7000000.0,"ordinaryProfit":6347000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":914000000.0,"incomeBeforeTax":5433000000.0,"incomeTaxes":1601000000.0,"netIncome":3831000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3819000000.0,"comprehensiveIncome":3216000000.0,"eps":31.72,"dilutedEps":null,"dividendPerShare":null,"per":70.33,"roe":0.0585,"cashFlowFromOperatingActivities":6339000000.0,"depreciationAndCashflowFromOperatingActivities":2921000000.0,"cashFlowFromInvestingActivities":-212000000.0,"cashFlowFromFinancialActivities":-946000000.0,"changesInCashAndCashEquivalents":4998000000.0,"列1":"asr","submitDate":"2020\/6\/26","stockCode":4974,"accountingYear":"第18期（自　2019年４月１日　至　2020年３月31日）","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.89,"cashAndCashEquivalents":16006000000.0,"assets":73593000000.0,"currentAssets":37798000000.0,"fixedAsset":35795000000.0,"tangibleFixedAssets":23798000000.0,"intangibleFixedAssets":10944000000.0,"investmentAndOtherAssets":1052000000.0,"liabilities":8013000000.0,"currentLiabilities":5876000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":2137000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":65580000000.0,"capitalStock":65801000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":17942000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":-317000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":6938000000.0,"costOfSales":2234000000.0,"grossProfit":4703000000.0,"sgaExpenses":4009000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1172000000.0,"operatingIncome":693000000.0,"nonOperatingIncome":81000000.0,"nonOperatingExpenses":29000000.0,"interestExpense":6000000.0,"ordinaryProfit":745000000.0,"extraordinaryGain":null,"extraordinaryLoss":8000000.0,"incomeBeforeTax":736000000.0,"incomeTaxes":326000000.0,"netIncome":410000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":404000000.0,"comprehensiveIncome":-48000000.0,"eps":3.36,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":3411000000.0,"depreciationAndCashflowFromOperatingActivities":815000000.0,"cashFlowFromInvestingActivities":-775000000.0,"cashFlowFromFinancialActivities":-944000000.0,"changesInCashAndCashEquivalents":1543000000.0,"列1":"q1r","submitDate":"2020\/8\/12","stockCode":4974,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":83926900.0,"sharesOwendPercent":0.697,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.868,"cashAndCashEquivalents":16360000000.0,"assets":77343000000.0,"currentAssets":36871000000.0,"fixedAsset":40472000000.0,"tangibleFixedAssets":28835000000.0,"intangibleFixedAssets":10273000000.0,"investmentAndOtherAssets":1363000000.0,"liabilities":10106000000.0,"currentLiabilities":7996000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":2110000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":67236000000.0,"capitalStock":67672000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":19812000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":-540000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":17393000000.0,"costOfSales":5565000000.0,"grossProfit":11827000000.0,"sgaExpenses":8090000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":2403000000.0,"operatingIncome":3736000000.0,"nonOperatingIncome":143000000.0,"nonOperatingExpenses":59000000.0,"interestExpense":12000000.0,"ordinaryProfit":3820000000.0,"extraordinaryGain":1000000.0,"extraordinaryLoss":539000000.0,"incomeBeforeTax":3281000000.0,"incomeTaxes":990000000.0,"netIncome":2291000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2274000000.0,"comprehensiveIncome":1608000000.0,"eps":18.89,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":5553000000.0,"depreciationAndCashflowFromOperatingActivities":1631000000.0,"cashFlowFromInvestingActivities":-2417000000.0,"cashFlowFromFinancialActivities":-1030000000.0,"changesInCashAndCashEquivalents":1897000000.0,"列1":"q2r","submitDate":"2020\/11\/12","stockCode":4974,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.84,"cashAndCashEquivalents":19467000000.0,"assets":83846000000.0,"currentAssets":43263000000.0,"fixedAsset":40582000000.0,"tangibleFixedAssets":29568000000.0,"intangibleFixedAssets":9782000000.0,"investmentAndOtherAssets":1231000000.0,"liabilities":13277000000.0,"currentLiabilities":11161000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":2115000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":70568000000.0,"capitalStock":71124000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":23265000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":-667000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":29549000000.0,"costOfSales":8297000000.0,"grossProfit":21251000000.0,"sgaExpenses":12460000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":3656000000.0,"operatingIncome":8791000000.0,"nonOperatingIncome":205000000.0,"nonOperatingExpenses":77000000.0,"interestExpense":18000000.0,"ordinaryProfit":8919000000.0,"extraordinaryGain":36000000.0,"extraordinaryLoss":596000000.0,"incomeBeforeTax":8359000000.0,"incomeTaxes":2610000000.0,"netIncome":5749000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":5726000000.0,"comprehensiveIncome":4940000000.0,"eps":47.56,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":7978000000.0,"depreciationAndCashflowFromOperatingActivities":2421000000.0,"cashFlowFromInvestingActivities":-1675000000.0,"cashFlowFromFinancialActivities":-1068000000.0,"changesInCashAndCashEquivalents":5004000000.0,"列1":"q3r","submitDate":"2021\/2\/12","stockCode":4974,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1539.0,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":85886100.0,"sharesOwendPercent":0.7132,"outstandingShares":null,"numberOfSubsidiary":8.0,"bps":616.05,"equityRatio":0.827,"cashAndCashEquivalents":23308000000.0,"assets":89750000000.0,"currentAssets":49115000000.0,"fixedAsset":40635000000.0,"tangibleFixedAssets":29766000000.0,"intangibleFixedAssets":9373000000.0,"investmentAndOtherAssets":1495000000.0,"liabilities":15448000000.0,"currentLiabilities":13191000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":2256000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":74302000000.0,"capitalStock":74945000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":27085000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":-763000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":46086000000.0,"costOfSales":14214000000.0,"grossProfit":31872000000.0,"sgaExpenses":17919000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":5545000000.0,"operatingIncome":13952000000.0,"nonOperatingIncome":308000000.0,"nonOperatingExpenses":101000000.0,"interestExpense":24000000.0,"ordinaryProfit":14159000000.0,"extraordinaryGain":518000000.0,"extraordinaryLoss":1125000000.0,"incomeBeforeTax":13552000000.0,"incomeTaxes":3971000000.0,"netIncome":9581000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":9547000000.0,"comprehensiveIncome":8674000000.0,"eps":79.29,"dilutedEps":null,"dividendPerShare":null,"per":37.43,"roe":0.1357,"cashFlowFromOperatingActivities":13943000000.0,"depreciationAndCashflowFromOperatingActivities":3220000000.0,"cashFlowFromInvestingActivities":-3778000000.0,"cashFlowFromFinancialActivities":-1103000000.0,"changesInCashAndCashEquivalents":8845000000.0,"列1":"asr","submitDate":"2021\/6\/29","stockCode":4974,"accountingYear":"第19期（自　2020年４月１日　至　2021年３月31日）","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.807,"cashAndCashEquivalents":29965000000.0,"assets":99658000000.0,"currentAssets":55537000000.0,"fixedAsset":44120000000.0,"tangibleFixedAssets":32918000000.0,"intangibleFixedAssets":9743000000.0,"investmentAndOtherAssets":1458000000.0,"liabilities":19071000000.0,"currentLiabilities":16825000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":2246000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":80586000000.0,"capitalStock":79044000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":31185000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":1393000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":15272000000.0,"costOfSales":2133000000.0,"grossProfit":13138000000.0,"sgaExpenses":4633000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1294000000.0,"operatingIncome":8504000000.0,"nonOperatingIncome":94000000.0,"nonOperatingExpenses":19000000.0,"interestExpense":6000000.0,"ordinaryProfit":8579000000.0,"extraordinaryGain":49000000.0,"extraordinaryLoss":67000000.0,"incomeBeforeTax":8561000000.0,"incomeTaxes":2517000000.0,"netIncome":6044000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6025000000.0,"comprehensiveIncome":8210000000.0,"eps":50.04,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":5604000000.0,"depreciationAndCashflowFromOperatingActivities":808000000.0,"cashFlowFromInvestingActivities":2403000000.0,"cashFlowFromFinancialActivities":-1881000000.0,"changesInCashAndCashEquivalents":6656000000.0,"列1":"q1r","submitDate":"2021\/8\/6","stockCode":4974,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":88162700.0,"sharesOwendPercent":0.7322,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.807,"cashAndCashEquivalents":21113000000.0,"assets":104777000000.0,"currentAssets":58107000000.0,"fixedAsset":46670000000.0,"tangibleFixedAssets":35469000000.0,"intangibleFixedAssets":9447000000.0,"investmentAndOtherAssets":1753000000.0,"liabilities":20011000000.0,"currentLiabilities":17768000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":2242000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":84766000000.0,"capitalStock":83027000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":35168000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":1565000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":31551000000.0,"costOfSales":8056000000.0,"grossProfit":23495000000.0,"sgaExpenses":9389000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":2659000000.0,"operatingIncome":14105000000.0,"nonOperatingIncome":179000000.0,"nonOperatingExpenses":43000000.0,"interestExpense":11000000.0,"ordinaryProfit":14241000000.0,"extraordinaryGain":1188000000.0,"extraordinaryLoss":1227000000.0,"incomeBeforeTax":14203000000.0,"incomeTaxes":4148000000.0,"netIncome":10054000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":10009000000.0,"comprehensiveIncome":12390000000.0,"eps":83.12,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":9914000000.0,"depreciationAndCashflowFromOperatingActivities":1670000000.0,"cashFlowFromInvestingActivities":-10686000000.0,"cashFlowFromFinancialActivities":-1992000000.0,"changesInCashAndCashEquivalents":-2195000000.0,"列1":"q2r","submitDate":"2021\/11\/12","stockCode":4974,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0},{"edinetCode":"E02474","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.841,"cashAndCashEquivalents":23935000000.0,"assets":106116000000.0,"currentAssets":60057000000.0,"fixedAsset":46058000000.0,"tangibleFixedAssets":35376000000.0,"intangibleFixedAssets":9245000000.0,"investmentAndOtherAssets":1436000000.0,"liabilities":16660000000.0,"currentLiabilities":14446000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":2214000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":89455000000.0,"capitalStock":87382000000.0,"capital":14965000000.0,"capitalSurplus":32893000000.0,"accumulatedEarnings":39523000000.0,"treasuryStock":null,"valuationAndConversionAdjustments":1887000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":45659000000.0,"costOfSales":11559000000.0,"grossProfit":34100000000.0,"sgaExpenses":14174000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4020000000.0,"operatingIncome":19926000000.0,"nonOperatingIncome":297000000.0,"nonOperatingExpenses":68000000.0,"interestExpense":17000000.0,"ordinaryProfit":20154000000.0,"extraordinaryGain":3205000000.0,"extraordinaryLoss":3245000000.0,"incomeBeforeTax":20114000000.0,"incomeTaxes":5696000000.0,"netIncome":14418000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":14364000000.0,"comprehensiveIncome":17080000000.0,"eps":119.29,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":15401000000.0,"depreciationAndCashflowFromOperatingActivities":2606000000.0,"cashFlowFromInvestingActivities":-13380000000.0,"cashFlowFromFinancialActivities":-2034000000.0,"changesInCashAndCashEquivalents":626000000.0,"列1":"q3r","submitDate":"2022\/2\/14","stockCode":4974,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E02474","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":14965,"settlementDate":"2022\/3\/31","submitterName":"タカラバイオ株式会社","submitterNameEnglish":"TAKARA BIO INC.","submitterNameKana":"タカラバイオカブシキガイシャ","location":"草津市野路東七丁目４番３８号","industory":"化学","corporateNumber":1160000000000.0}]